{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T19:08:22Z","timestamp":1782846502796,"version":"3.54.5"},"reference-count":32,"publisher":"JMIR Publications Inc.","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JMIR Res Protoc"],"abstract":"Abstract<\/jats:title>\n \n Background<\/jats:title>\n Computed tomography (CT)\u2013guided online stereotactic adaptive radiotherapy (CT-STAR) allows for ablative radiation doses to be delivered to selected patients with borderline resectable (BR) or locally advanced pancreatic cancer (LAPC) or unresectable pancreatic cancer. However, the use of CT-STAR to deliver an ablative dose to the pancreas while minimizing gastrointestinal (GI) side effects to reduce acute and late toxicity rates compared to historic controls has yet to be prospectively evaluated.<\/jats:p>\n <\/jats:sec>\n \n Objective<\/jats:title>\n The primary objective of this prospective, single-arm, multicenter phase 2 clinical trial (Adaptive Radiation Therapy Individualized Approach [ARTIA]\u2013Pancreas) is to evaluate the rate of acute grade 3+ GI toxicity in patients with BR\/LAPC treated with ablatively dosed CT-STAR compared to historical controls.<\/jats:p>\n <\/jats:sec>\n \n Methods<\/jats:title>\n Patients with histologically or cytologically confirmed BR, locally advanced, or medically inoperable pancreatic adenocarcinoma are eligible for participation. Consenting and eligible patients will be treated with CT-STAR, delivering 5 fractions over 1 to 2 weeks with daily adaptation based on anatomic changes observed with onboard cone beam CT imaging. The primary end point of this trial is the rate of acute patient-reported grade 3+ treatment-related GI toxicities, assessed at 90 days post CT-STAR and compared to a historical control rate of 20%. The key powered secondary end point is the rate of long-term patient-reported grade 3+ treatment-related GI toxicities, evaluated at 12 months post CT-STAR and compared to a historical control rate of 25%. Additional secondary end points include overall survival, local (in-field) control rates, and distant progression-free survival at 1 and 2 years post CT-STAR.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n Study completion is anticipated in February 2029, and the final study results will be published upon completion of the study.<\/jats:p>\n <\/jats:sec>\n \n Conclusions<\/jats:title>\n ARTIA-Pancreas represents the first prospective phase 2 clinical trial to evaluate whether CT-STAR can reduce the rate of acute patient-reported GI toxicities in patients with BR\/LAPC compared to historical controls. Findings from this clinical trial will provide evidence for safely and effectively incorporating ablatively dosed adaptive radiotherapy into treatment regimens for this population.<\/jats:p>\n <\/jats:sec>","DOI":"10.2196\/84607","type":"journal-article","created":{"date-parts":[[2026,2,23]],"date-time":"2026-02-23T21:26:33Z","timestamp":1771881993000},"page":"e84607-e84607","source":"Crossref","is-referenced-by-count":1,"title":["Stereotactic Adaptive Radiation Therapy for Borderline Resectable or Locally Advanced Pancreatic Cancer to Minimize Gastrointestinal Toxicity (ARTIA-Pancreas): Protocol for a Single-Arm Prospective Trial"],"prefix":"10.2196","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2208-3241","authenticated-orcid":false,"given":"Lauren E","family":"Henke","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4029-8764","authenticated-orcid":false,"given":"Hyun","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4362-3182","authenticated-orcid":false,"given":"Eric","family":"Laugeman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-7677-9141","authenticated-orcid":false,"given":"Steven","family":"Kohlmyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7595-2733","authenticated-orcid":false,"given":"Claire","family":"McCann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-2964-7040","authenticated-orcid":false,"given":"Kate","family":"Pietrovito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0687-0897","authenticated-orcid":false,"given":"Kenneth","family":"Russell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7497-8816","authenticated-orcid":false,"given":"Jennifer","family":"Woo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9054-6474","authenticated-orcid":false,"given":"Alex T","family":"Price","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1010","published-online":{"date-parts":[[2026,2,23]]},"reference":[{"issue":"11","key":"R1","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1007\/s00595-007-3745-8","article-title":"Surgery versus radiochemotherapy for resectable locally invasive pancreatic cancer: final results of a randomized multi-institutional trial","volume":"38","author":"Doi","journal-title":"Surg Today"},{"issue":"17","key":"R2","doi-asserted-by":"publisher","first-page":"1605","DOI":"10.1056\/NEJMra0901557","article-title":"Pancreatic cancer","volume":"362","author":"Hidalgo","journal-title":"N Engl J Med"},{"issue":"5","key":"R3","doi-asserted-by":"publisher","first-page":"1166","DOI":"10.1016\/j.ijrobp.2012.02.051","article-title":"A phase I\/II trial of intensity modulated radiation (IMRT) dose escalation with concurrent fixed-dose rate gemcitabine (FDR-G) in patients with unresectable pancreatic cancer","volume":"84","author":"Ben-Josef","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"17","key":"R4","doi-asserted-by":"publisher","first-page":"1844","DOI":"10.1001\/jama.2016.4324","article-title":"Effect of chemoradiotherapy vs chemotherapy on survival in patients with locally advanced pancreatic cancer controlled after 4 months of gemcitabine with or without erlotinib: the LAP07 randomized clinical trial","volume":"315","author":"Hammel","journal-title":"JAMA"},{"issue":"4","key":"R5","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1002\/jso.23392","article-title":"Outcomes with FOLFIRINOX for borderline resectable and locally unresectable pancreatic cancer","volume":"108","author":"Boone","journal-title":"J Surg Oncol"},{"issue":"1","key":"R6","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1097\/COC.0000000000000003","article-title":"Induction chemotherapy followed by concurrent full-dose gemcitabine and intensity-modulated radiation therapy for borderline resectable and locally advanced pancreatic adenocarcinoma","volume":"39","author":"Badiyan","journal-title":"Am J Clin Oncol"},{"issue":"15","key":"R7","doi-asserted-by":"publisher","first-page":"2692","DOI":"10.1002\/cncr.28117","article-title":"A multi-institutional phase 2 study of neoadjuvant gemcitabine and oxaliplatin with radiation therapy in patients with pancreatic cancer","volume":"119","author":"Kim","journal-title":"Cancer"},{"issue":"1","key":"R8","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.radonc.2004.12.022","article-title":"Phase-II study on stereotactic radiotherapy of locally advanced pancreatic carcinoma","volume":"76","author":"Hoyer","journal-title":"Radiother Oncol"},{"issue":"4","key":"R9","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1016\/j.ijrobp.2015.12.003","article-title":"Focal radiation therapy dose escalation improves overall survival in locally advanced pancreatic cancer patients receiving induction chemotherapy and consolidative chemoradiation","volume":"94","author":"Krishnan","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"5","key":"R10","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1001\/jamaoncol.2021.0057","article-title":"Association of ablative radiation therapy with survival among patients with inoperable pancreatic cancer","volume":"7","author":"Reyngold","journal-title":"JAMA Oncol"},{"issue":"1","key":"R11","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/j.radonc.2014.10.015","article-title":"SBRT in pancreatic cancer: what is the therapeutic window?","volume":"114","author":"Brunner","journal-title":"Radiother Oncol"},{"issue":"5","key":"R12","doi-asserted-by":"publisher","first-page":"1399","DOI":"10.1016\/j.ijrobp.2020.09.022","article-title":"Randomized, double-blinded, placebo-controlled multicenter adaptive phase 1-2 trial of GC 4419, a dismutase mimetic, in combination with high dose stereotactic body radiation therapy (SBRT) in locally advanced pancreatic cancer (PC)","volume":"108","author":"Hoffe","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"Suppl 1","key":"R13","doi-asserted-by":"publisher","first-page":"i53","DOI":"10.1093\/jrr\/rrw016","article-title":"Hypofractionated ablative radiotherapy for locally advanced pancreatic cancer","volume":"57","author":"Crane","journal-title":"J Radiat Res"},{"issue":"6","key":"R14","doi-asserted-by":"publisher","first-page":"894","DOI":"10.1097\/SLA.0000000000005080","article-title":"Local control and survival after induction chemotherapy and ablative radiation versus resection for pancreatic ductal adenocarcinoma with vascular involvement","volume":"274","author":"Jolissaint","journal-title":"Ann Surg"},{"issue":"3","key":"R15","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1016\/j.semradonc.2019.02.004","article-title":"Practical clinical workflows for online and offline adaptive radiation therapy","volume":"29","author":"Green","journal-title":"Semin Radiat Oncol"},{"issue":"3","key":"R16","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1016\/j.radonc.2017.11.032","article-title":"Phase I trial of stereotactic MR-guided online adaptive radiation therapy (SMART) for the treatment of oligometastatic or unresectable primary malignancies of the abdomen","volume":"126","author":"Henke","journal-title":"Radiother Oncol"},{"issue":"3","key":"R17","doi-asserted-by":"publisher","first-page":"668","DOI":"10.1016\/j.ijrobp.2025.03.049","article-title":"Feasibility of stereotactic body radiation therapy for pancreatic tumors abutting organs at risk using magnetic resonance guided adaptive radiation therapy","volume":"122","author":"D\u2019Souza","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"5","key":"R18","doi-asserted-by":"publisher","first-page":"2123","DOI":"10.1002\/cam4.2100","article-title":"Using adaptive magnetic resonance image-guided radiation therapy for treatment of inoperable pancreatic cancer","volume":"8","author":"Rudra","journal-title":"Cancer Med"},{"issue":"1","key":"R19","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1016\/j.ijrobp.2022.07.015","article-title":"MR-guided radiation therapy with concurrent gemcitabine\/nab-paclitaxel chemotherapy in inoperable pancreatic cancer: a TITE-CRM phase I trial","volume":"115","author":"Kim","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"4","key":"R20","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1016\/j.ijrobp.2023.05.023","article-title":"A multi-institutional phase 2 trial of ablative 5-fraction stereotactic magnetic resonance-guided on-table adaptive radiation therapy for borderline resectable and locally advanced pancreatic cancer","volume":"117","author":"Parikh","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"2","key":"R21","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1016\/j.prro.2020.09.005","article-title":"Ablative 5-fraction stereotactic magnetic resonance\u2013guided radiation therapy with on-table adaptive replanning and elective nodal irradiation for inoperable pancreas cancer","volume":"11","author":"Chuong","journal-title":"Pract Radiat Oncol"},{"key":"R22","doi-asserted-by":"publisher","DOI":"10.1016\/j.radonc.2023.110064","article-title":"Stereotactic MR-guided on-table adaptive radiation therapy (SMART) for borderline resectable and locally advanced pancreatic cancer: a multi-center, open-label phase 2 study","volume":"191","author":"Chuong","journal-title":"Radiother Oncol"},{"issue":"4","key":"R23","doi-asserted-by":"publisher","first-page":"918","DOI":"10.1016\/j.ijrobp.2024.10.026","article-title":"NRG oncology international consensus contouring atlas on target volumes and dosing strategies for dose-escalated pancreatic cancer radiation therapy","volume":"121","author":"Sanford","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"7","key":"R24","doi-asserted-by":"publisher","first-page":"1128","DOI":"10.1002\/cncr.29161","article-title":"Phase 2 multi-institutional trial evaluating gemcitabine and stereotactic body radiotherapy for patients with locally advanced unresectable pancreatic adenocarcinoma","volume":"121","author":"Herman","journal-title":"Cancer"},{"issue":"5","key":"R25","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1016\/j.prro.2019.06.016","article-title":"Radiation therapy for pancreatic cancer: executive summary of an ASTRO clinical practice guideline","volume":"9","author":"Palta","journal-title":"Pract Radiat Oncol"},{"issue":"6","key":"R26","doi-asserted-by":"publisher","DOI":"10.3390\/cancers16061206","article-title":"Adaptive radiotherapy: next-generation radiotherapy","volume":"16","author":"Dona Lemus","journal-title":"Cancers (Basel)"},{"issue":"11","key":"R27","doi-asserted-by":"publisher","first-page":"e1378","DOI":"10.1200\/JOP.19.00605","article-title":"Time-driven activity-based costing comparison of CT-guided versus MR-guided SBRT","volume":"16","author":"Parikh","journal-title":"JCO Oncol Pract"},{"key":"R28","doi-asserted-by":"publisher","DOI":"10.1016\/j.radonc.2022.11.017","article-title":"Prospective imaging comparison of anatomic delineation with rapid kV cone beam CT on a novel ring gantry radiotherapy device","volume":"178","author":"Henke","journal-title":"Radiother Oncol"},{"key":"R29","doi-asserted-by":"publisher","DOI":"10.1016\/j.radonc.2022.08.026","article-title":"Simulated computed tomography-guided stereotactic adaptive radiotherapy (CT-STAR) for the treatment of locally advanced pancreatic cancer","volume":"175","author":"Schiff","journal-title":"Radiother Oncol"},{"issue":"1","key":"R30","doi-asserted-by":"publisher","DOI":"10.1186\/s13014-022-02125-z","article-title":"The first reported case of a patient with pancreatic cancer treated with cone beam computed tomography\u2013guided stereotactic adaptive radiotherapy (CT-STAR)","volume":"17","author":"Kim","journal-title":"Radiat Oncol"},{"issue":"3","key":"R31","doi-asserted-by":"publisher","DOI":"10.1016\/j.adro.2022.101034","article-title":"Online adaptive radiation therapy and opportunity cost","volume":"8","author":"McComas","journal-title":"Adv Radiat Oncol"},{"issue":"1","key":"R32","doi-asserted-by":"publisher","DOI":"10.1016\/j.adro.2020.06.010","article-title":"Ablative five-fraction stereotactic body radiation therapy for inoperable pancreatic cancer using online MR-guided adaptation","volume":"6","author":"Hassanzadeh","journal-title":"Adv Radiat Oncol"}],"container-title":["JMIR Research Protocols"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.researchprotocols.org\/2026\/1\/e84607","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T18:18:41Z","timestamp":1782843521000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.researchprotocols.org\/2026\/1\/e84607"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,23]]},"references-count":32,"URL":"https:\/\/doi.org\/10.2196\/84607","relation":{},"ISSN":["1929-0748"],"issn-type":[{"value":"1929-0748","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,23]]},"article-number":"v15i11e84607"}}